جست‌وجوی استاد و پژوهشگر

Ruth Etzioniمشاهده پروفایل

استاد مدعو

• Cancer Screening
• Prostate Cancer Research
• Biomarkers
• +۵ مورد دیگر

Ruth Etzioni is an Affiliate Professor in the Biostatistics Program and Public Health Sciences Division at the Fred Hutchinson Cancer Center. She leads the Etzioni Lab, focusing on cancer screening, early detection, and overdiagnosis analysis. Her work integrates statistical modeling, epidemiology, and clinical research to address critical questions in prostate and breast cancer control. Dr. Etzioni holds the Rosalie & Harold Rea Brown Endowed Chair and has received a $7.4M NIH Outstanding Investigator Award. Education: PhD in Statistics (Carnegie Mellon University, 1990), MS in Statistics (Carnegie Mellon, 1987), BS in Mathematics (University of Cape Town, South Africa). Research interests emphasize biomarkers, clinical trials, and epidemiological methods. She leads the Biostatistics Core for the Pacific Northwest Prostate Cancer SPORE and participates in the Cancer Intervention and Surveillance Modeling Network (CISNET). Her lab develops models to evaluate screening policies, quantify overdiagnosis, and inform healthcare disparities reduction strategies. Key achievements include groundbreaking work on prostate cancer screening's harm-benefit tradeoffs and contributions to multi-cancer early detection (MCED) frameworks. Recent studies address racial disparities in prostate cancer outcomes, metastasis trends, and the clinical utility of novel diagnostics like PSMA PET imaging. Awards include the Brown Endowed Chair (2020), NCI OIA Award (2023), and recognition for advancing cancer data science. Her lab collaborates with institutions globally and mentors students in biostatistics and translational data science.

John F Valliantمشاهده پروفایل

استاد

• Radiopharmaceutical Chemistry
• Nuclear Medicine
• Molecular Imaging
• +۵ مورد دیگر

John F Valliant is a Professor in the Department of Chemistry and Chemical Biology at McMaster University. His research focuses on radiopharmaceutical chemistry, molecular imaging, and targeted therapies, particularly in cancer diagnostics and therapeutics. He co-founded Fusion Pharmaceuticals, a company acquired by AstraZeneca for $2.4 billion (US), which specializes in targeted alpha therapy for cancer treatment. His work includes developing radiolabeled imaging agents for prostate cancer (e.g., [18F]DCFPyL), targeted alpha therapies (e.g., FPI-1434), and bioorthogonal chemistry strategies for pretargeted imaging. Valliant has contributed to advancements in photoacoustic imaging, SPECT/PET modalities, and theranostic agents for conditions like bacterial infections and bone diseases. Key projects include the Phase II clinical trial using 18F-DCFPyL PET-MRI for oligometastatic prostate cancer and studies on individualized dosimetry in Lu-177 therapies. He has pioneered platforms for radiolabeled antibody-recruiting molecules and fluorous-phase chemistry for high-specific-activity probes. Valliant’s research bridges disciplines, integrating chemistry, biology, and clinical applications to address unmet medical needs in oncology and diagnostic imaging.

• Biomedical Imaging
• Medical Imaging Physics
• Motion Compensation in Imaging
• +۵ مورد دیگر

Associate Professor Andre Kyme is an academic staff member in the School of Biomedical Engineering at The University of Sydney. His research focuses on developing enabling technologies for biomedical imaging, including motion compensation in MRI/PET, robotic platforms for image-guided therapy, and cross-disciplinary applications like plant salt uptake analysis using PET. He collaborates with institutions globally and advises students on projects like lameness detection in horses and AI-based motion correction. Research Interests: Kyme's work spans motion correction in medical imaging modalities, medical robotics integration with imaging systems, and innovative applications of imaging technologies in non-traditional fields. His team emphasizes leveraging advancements in computer vision, machine learning, and instrumentation to improve imaging performance and accessibility. Recent Projects: Current research includes MRI-compatible robotic platforms for therapy applications, AI-driven lameness detection in horses, and pediatric neuroimaging improvements. He leads the BREEZE initiative to enhance MRI accessibility for children with cerebral palsy through eye-gaze communication technology. Publications: His work spans 20+ years with over 50 peer-reviewed publications in journals like Physics in Medicine and Biology and IEEE Transactions. Key areas include PET/SPECT/CT motion correction algorithms, robotic systems for medical imaging, and novel imaging applications in plant science. Teaching: Kyme instructs core biomedical engineering courses including thesis supervision and capstone projects at both undergraduate and postgraduate levels. Labs/Teams: Active in the Brain and Mind Centre and Biomedical Imaging, Visualisation and Information Technologies groups at Sydney. Collaborates with industry partners like TeleMedVet and academic institutions including University of California Davis and Chinese University of Hong Kong.

Wolfgang Weberمشاهده پروفایل

استاد

• Molecular Imaging
• Targeted Radionuclide Therapy
• Theranostics
• +۳ مورد دیگر

Prof. Wolfgang Weber is a Professor and Director of the Department of Nuclear Medicine at the Klinikum rechts der Isar, Technical University of Munich (TUM). His academic career includes roles such as Associate Professor at UCLA (2003–2007) and Chair of Nuclear Medicine at Albert Ludwig University of Freiburg (2007–2013). He specializes in molecular imaging and targeted radionuclide therapy, with a focus on cancer theranostics. His research addresses precision oncology through advanced imaging techniques for diagnosis and treatment monitoring. Education: Doctorate in Medicine from TUM (1995). Key prior appointments include Director of the Molecular Imaging and Therapy Service at Memorial Sloan Kettering Cancer Center (2013–2017) and Professor at Weill-Cornell Medical College. His work spans prostate cancer imaging, neuroendocrine tumors, and radiopharmaceutical development. Research interests emphasize integrating imaging modalities like PET/CT and SPECT for cancer staging, therapy response prediction, and novel radiotracer development. Notable contributions include PSMA-ligand PET imaging for prostate cancer recurrence detection and PARP inhibitor engagement studies in lung cancer. Publications highlight innovations in theranostic agents, such as 18F-rhPSMA-7 and Ga-68-based tracers. His work frequently addresses clinical trial validation of imaging biomarkers and dosimetry safety in radiolabeled therapies.

Rune Sundsetمشاهده پروفایل

دانشیار

• Nuclear Medicine
• Radiation Biology
• Radiopharmaceutical Development
• +۳ مورد دیگر

Rune Sundset is an Associate Professor at UiT The Arctic University of Norway, affiliated with the Nuclear Medicine and Radiation Biology research group. His work focuses on radiopharmaceutical development, molecular imaging, and liposomal drug delivery systems. Research themes: Radioligand design, PET/SPECT imaging optimization, and nanoparticle-biology interactions Key collaborations: European Journal of Nuclear Medicine and Molecular Imaging, BMC Research Notes, and Acta Physiologica Recent publications highlight his contributions to: Development of Cu-67 and Ga-68 radiotracers for tumor imaging Liposomal formulations for arginase inhibition in cancer therapy Machine learning applications in dynamic PET imaging Sphingolipid effects on liposome uptake by human phagocytes In the SECURE project, he investigates radioligand therapy and imaging biomarkers. His research group (NMRB) spans nuclear medicine, radiation biology, and biomedical engineering, with applications in glioblastoma, prostate cancer, and neurodegenerative diseases.

Henry VanBrocklinمشاهده پروفایل

استاد

• Radiopharmaceutical Chemistry
• PET Imaging
• SPECT Imaging
• +۵ مورد دیگر

Henry VanBrocklin, PhD, is a Professor in Residence and Director of the Radiopharmaceutical Research Program in the Center for Molecular and Functional Imaging (CMFI) at the University of California, San Francisco. He also serves as a Joint Faculty Scientist at the Lawrence Berkeley National Laboratory and is a core faculty member for the Master's in Biomedical Imaging (MSBI) program. Dr. VanBrocklin received his educational training from: Doctor of Philosophy: Washington University, St. Louis - Radiopharmaceutical Chemistry Postdoctoral Fellow: University of Illinois, Urbana Dr. VanBrocklin's research focuses on radiopharmaceutical chemistry and molecular imaging. His work centers on developing novel radiotracers for PET and SPECT imaging applications, with particular emphasis on cancer imaging (prostate, pancreatic, and breast cancer) and neurological imaging. His laboratory specializes in short-lived radioisotope production and the creation of fluorine-18 and carbon-11 labeling chemistry strategies for new radiotracer preparations. His recent publications demonstrate a strong focus on prostate cancer imaging and therapy using PSMA-targeted agents, CD46-targeted theranostics, and novel nanocarrier systems for enhanced tumor penetration. There's also significant work on T-cell imaging using [18F]F-AraG for applications in infectious disease, autoimmune disorders, and cancer immunotherapy monitoring. Dr. VanBrocklin has received numerous prestigious awards: Paul C. Aebersold Award, SNMMI, 2023 Western Pioneer Award, Western Regional SNMMI, 2022 Fellow, Society of Radiopharmaceutical Sciences, SRS, 2021 Michael J. Welch Award, RPSC, SNMMI, 2020 MSBI Outstanding Teacher Award (2019, 2021, 2023) Distinguished Investigator, Acad Radiol & Biomed Imag Res, 2018 Fellow, Society of Nuclear Medicine and Molecular Imaging, SNMMI, 2018 As Director of the Radiopharmaceutical Research Program at UCSF's CMFI, Dr. VanBrocklin oversees a major research operation that develops and produces radiotracers for both basic science and clinical research. His laboratory has secured significant funding for developing novel imaging agents and therapeutic approaches, particularly in the area of targeted alpha therapy for prostate cancer. He serves as Editor-in-Chief of Molecular Imaging (2011-2025) and has been instrumental in advancing regulatory frameworks for PET drug development. Dr. VanBrocklin leads the Radiopharmaceutical Research Program at UCSF's Center for Molecular and Functional Imaging, which includes radiochemistry laboratories, imaging facilities, and a team of researchers focused on developing novel radiotracers and imaging methodologies. His program collaborates extensively with the Lawrence Berkeley National Laboratory, where he holds a joint appointment, facilitating access to advanced isotope production capabilities.

• Nuclear Medicine
• Medical Imaging
• Oncology
• +۵ مورد دیگر

Dr. Isis W. Gayed is an Adjunct Professor in the Radiology & Imaging Sciences department. She is a board-certified nuclear medicine physician with additional certification in nuclear cardiology. Education: MBBS from Faculty of Medicine, University of Khartoum Fellowship at Baylor College of Medicine Residency at Baylor College of Medicine Internship at Hahnemann University Hospital Graduate Training at Michener Institute School of Applied Health Sciences Post-Graduate Training at Toronto General Hospital Research Interests: Nuclear medicine applications in cancer imaging (PET-CT, SPECT/CT) Cardiovascular imaging in oncology patients Diagnostic accuracy of imaging modalities Lymphatic mapping and sentinel node detection Functional imaging for treatment planning Endocrine and parathyroid imaging Publication Trends: Over 20 peer-reviewed articles in clinical nuclear medicine Focus areas: oncology imaging, cardiovascular nuclear medicine, diagnostic techniques Collaborative research with surgical and oncology departments Methodological improvements in SPECT/CT and PET-CT applications Longitudinal studies on radiation therapy outcomes Technical innovations in parathyroid and breast cancer imaging Professional Background: Board certifications in nuclear medicine and nuclear cardiology Extensive clinical training across North America Primary research focus on hybrid imaging modalities (SPECT/CT, PET/CT) Contributions to cancer imaging guidelines and treatment protocols

• Nuclear Medicine
• Medical Imaging
• Oncology Imaging
• +۵ مورد دیگر

Walter Noordzij is an Assistant Professor at the University of Groningen within the Faculty of Medical Sciences , affiliated with the Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE) group. His research focuses on nuclear medicine imaging technologies , particularly PET/CT applications in oncology, cardiology, and healthcare economics. He has contributed to studies on cardiac sympathetic innervation in amyloidosis, financial literacy of medical residents regarding imaging costs, and prostate cancer management using PSMA PET/CT. Recent work also addresses physician workload trends in Dutch nuclear medicine and innovative parametric imaging techniques. Research interests include positron emission tomography-computed tomography (PET/CT) , fluorodeoxyglucose (FDG) imaging , and multidisciplinary approaches to prostate cancer diagnosis . He actively collaborates internationally, evidenced by his participation in the 19th International Conference on Radiation Therapy and the EANM Focus Meeting on Prostate Cancer . No awards are explicitly listed, but his involvement in high-impact studies suggests active recognition in the field. He has supervised 3 students but their names are not disclosed. His work spans clinical imaging methodology, translational research, and healthcare system analysis, reflecting a commitment to bridging basic science and clinical practice.

Rimma Axelssonمشاهده پروفایل

استاد

• Cancer and Oncology
• Radiology and Medical Imaging
• Nuclear Medicine
• +۳ مورد دیگر

Rimma Axelsson is a Professor of Nuclear Medicine and Senior Physician at Karolinska Institutet, affiliated with the Department of Molecular Medicine and Surgery. She holds leadership roles as founder of the Theranostics Trial Center and program leader for the Theranostics Trial Alliance Sweden. Her expertise spans nuclear medicine, radiology, and molecular imaging. Education: MD (1995), PhD (2000, Karolinska Institutet), Specialist in Nuclear Medicine (1997) and Radiology (2000), Docent (2006), and Adjunct Professor (2012–2022). Research focuses on theranostics, PET imaging for cancer therapy selection, and molecular diagnostics. Key areas include HER2 targeting, PSMA imaging, and FAPI-46 applications. She leads grants on TROP-2 targeted radiopharmaceuticals and imaging advancements in prostate cancer staging. Publications emphasize precision medicine, radiopharmaceutical development, and oncologic imaging. Her work bridges clinical practice and research, aiming to personalize cancer treatment through molecular imaging.

Chang-Hoon Choiمشاهده پروفایل

پژوهشگر

• Magnetic Resonance Imaging (MRI)
• Magnetic Resonance Spectroscopy (MRS)
• Ultra-High Field MRI
• +۸ مورد دیگر

Dr. Chang-Hoon Choi is a researcher at the Institute of Neurosciences and Medicine (INM) , Forschungszentrum Jülich GmbH, Germany, with a focus on Medical Imaging Physics (INM-4) . His work bridges Magnetic Resonance Imaging (MRI) , PET-MRI hybrid systems , and RF coil instrumentation for neuroscience applications. Research Highlights: Development of double-tuned coils for 1H/X-nuclei imaging, ultra-high field MRI systems , and MR-PET hybrid technologies . Technical Expertise: Specializes in RF antenna arrays , signal optimization , and multinuclear MRI/MRS for brain studies. Key Article Trends : Over 15 recent publications emphasize coil design innovations (e.g., butterfly, dipole, and birdcage coils), hybrid MR-PET/SPECT systems , and neurochemical dynamics via tDCS-MRS integration and phosphorus/sodium imaging . Methodological advances include free water elimination in diffusion MRI , quantum filtering , and shielding techniques for UHF-MR systems . Applications : His work targets stroke , epilepsy , brain tumors , and neuroplasticity studies using preclinical animal models (rat, chick embryo) and translational hardware (e.g., 9.4T systems).

• Diagnostic Imaging
• Medical Imaging
• Oncology
• +۷ مورد دیگر

Clinical Professor Paul Roach is affiliated with the University of Sydney's Northern Clinical School, specializing in Medical Imaging. His research focuses on diagnostic imaging techniques (e.g., PET/CT, SPECT/CT) applied to neuroendocrine tumors, thyroid cancer, and oncology. He has contributed to advancements in theranostic approaches, biomarker development, and radiation therapy protocols. Key research interests include: Peptide receptor radionuclide therapy (PRRT) efficacy and safety PET/CT imaging for neuroendocrine neoplasms Prognostic biomarkers like NETPET score Thyroid cancer management and radioactive iodine practices Recent articles highlight innovations in dual modality imaging, PRRT outcomes, and biomarker validation. His work has been published in journals like Journal of Nuclear Medicine and Theranostics . Collaborative grants include studies on nasal mesh nebulizers and thyroid cancer management. Notable projects include the TROG 18.06 glioblastoma trial and the Australasian consensus on hormonal crises during PRRT. His clinical expertise bridges molecular imaging with oncological treatment strategies.

• Radiopharmaceutical Cancer Research
• Molecular Imaging
• Cancer Biology
• +۳ مورد دیگر

Prof. Dr. Jens Pietzsch is the Head of the Radiopharmaceutical and Chemical Biology department at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR). His research focuses on radiopharmaceutical cancer research, molecular imaging, and therapeutic targeting of cyclooxygenase (COX) pathways. His work bridges medical imaging , oncology , and pharmaceutical chemistry , with a strong emphasis on neuroendocrine tumors, melanoma, and prostate cancer. Institutional Affiliation : Helmholtz-Zentrum Dresden-Rossendorf (HZDR) Department : Radiopharmaceutical and Chemical Biology Prof. Pietzsch's research integrates radiopharmacology , bioinorganic chemistry , and biomaterials . Key areas include: Development of COX-2 inhibitors as anti-cancer agents Radiolabeled peptides for PET/SPECT imaging Design of theranostic radionuclide pairs (e.g., 133La/225Ac) Investigation of macrophage-tumor interactions in glioma progression His recent publications (2024-2026) highlight trends in carborane-based drug analogs , NO-releasing therapeutics , and multimodal imaging for tumor targeting. Articles emphasize PSMA ligands , Eph receptor imaging , and biomaterial platforms for cancer modeling.

• Pharmaceutical Sciences
• Radiopharmaceuticals
• Medical Imaging
• +۳ مورد دیگر

Theresa Balber is a researcher affiliated with the Faculty of Life Sciences and Faculty of Chemistry at an unspecified institution. Her work focuses on pharmaceutical sciences, medical imaging, and cancer research, with a strong emphasis on radiopharmaceutical development and multimodal imaging techniques. School: Faculty of Life Sciences Department: Department of Pharmaceutical Sciences Academic Rank: Researcher Her research explores tracer development for PARP imaging, quantification methods in preclinical PET/MRI, dual-tracer SPECT for prostate cancer, bioconjugation chemistry for radiolabeled compounds, and gadolinium-free contrast agents. Publications highlight her contributions to improving radiolabeling efficiency, stability, and cancer cell targeting. Recent trends in her work include advancements in molecular imaging, noninvasive monitoring of DNA repair mechanisms, and mucoadhesive materials for diagnostics. Collaborations span institutions in Austria and involve preclinical in vivo and in vitro studies.

• Radiopharmaceuticals
• Molecular Imaging
• Cancer Theranostics
• +۸ مورد دیگر

Anna Orlova is a Professor at Uppsala University, holding dual appointments at the Department of Medicinal Chemistry; Theranostics and the Department of Immunology, Genetics and Pathology within the Research Program: Cancer Precision Medicine. Her work focuses on developing novel radiopharmaceuticals for cancer imaging and therapy, with particular expertise in affibody molecules, peptide-based radiotracers, and theranostic approaches for prostate and breast cancer. Her research spans multiple areas of nuclear medicine and molecular imaging, with emphasis on PSMA, GRPR, and HER2 targeting for cancer diagnostics and therapy. She has pioneered work in affibody-drug conjugates, pretargeting strategies, and optimizing radiolabeling techniques for improved tumor targeting and reduced off-target effects. Her laboratory investigates both diagnostic imaging probes and therapeutic radiopharmaceuticals, often working on theranostic pairs that use the same targeting vector for both diagnosis and treatment. Dr. Orlova's recent publications demonstrate a strong focus on translating preclinical findings to clinical applications, with multiple first-in-human studies and phase I/II clinical trials. Her work has significantly advanced the field of targeted radionuclide therapy, particularly in optimizing pharmacokinetics through albumin-binding domains and developing novel chelation strategies for improved imaging contrast and therapeutic efficacy. Her scientific contributions include numerous publications in high-impact journals such as ACS Pharmacology & Translational Science, EJNMMI Radiopharmacy and Chemistry, and Journal of Controlled Release. She collaborates extensively with researchers across Uppsala University and internationally, particularly with Vladimir Tolmachev's research group in the Department of Immunology, Genetics and Pathology. Dr. Orlova maintains active research programs in multiple areas of cancer theranostics, with ongoing projects focused on improving tumor targeting, reducing hepatic uptake of radiopharmaceuticals, and developing novel therapeutic approaches for cancers with low target expression. Her work bridges basic science with clinical translation, aiming to bring innovative imaging and therapeutic agents to patients with prostate cancer, breast cancer, and other malignancies.

Yuni Dewarajaمشاهده پروفایل

استاد پژوهشی

• Radiation absorbed dose estimation
• Quantitative SPECT imaging
• Image reconstruction
• +۶ مورد دیگر

Yuni Dewaraja, PhD is the William Martel Research Professor in the Department of Radiology at the University of Michigan Medical School. She is affiliated with the Center for Positron Emission Tomography and has made significant contributions to the field of nuclear medicine physics and radiopharmaceutical therapy dosimetry. Dr. Dewaraja earned her PhD in 1994 from the University of Michigan, following an MS from Kansas State University in 1990 and a BS from the University of Western Australia in 1986. Her academic journey has positioned her as a leading expert in quantitative imaging and radiation dosimetry. Dr. Dewaraja's research focuses on estimating radiation absorbed dose in radionuclide therapy , quantitative SPECT imaging , image reconstruction techniques , and correction methods for scatter, attenuation and partial volume effects . She extensively employs Monte Carlo methods for image reconstruction and patient-specific absorbed dose estimation. Her work bridges physics, engineering, and clinical applications to improve the precision of targeted radionuclide therapies. Her recent publications demonstrate a strong emphasis on Lutetium-177 and Yttrium-90 therapies , with research spanning dosimetry standardization , predictive modeling of treatment response , optimization of imaging protocols , and integration of multiple therapeutic modalities . She has been instrumental in international efforts to reduce variability in dosimetry calculations and establish best practices in the field. Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Multicycle Dosimetric Behavior and Dose–Effect Relationships in [177Lu]Lu-DOTATATE Therapy Shorter SPECT scans using self-supervised coordinate learning techniques Sequential 90Y SIRT and SBRT using PET-based Absorbed Dose Maps 177Lu-PSMA-617 SPECT/CT Dosimetry and Radiobiological Models Dr. Dewaraja has received recognition through numerous citations of her work, with over 3,000 total citations according to the Michigan Research Experts profile. Her research has been featured in leading journals including the Journal of Nuclear Medicine (93 publications), European Journal of Nuclear Medicine and Molecular Imaging (30 publications), and Medical Physics (12 publications). As a dedicated educator and mentor, Dr. Dewaraja collaborates extensively with colleagues across multiple institutions on research projects focused on advancing precision in nuclear medicine therapy. Her work has significant implications for improving the safety and efficacy of targeted radionuclide treatments for cancer patients.